​

Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

ASND Stock Forecast

Ascendis Pharma (ASND) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $242.00, with a high of $254.00 and a low of $230.00. This represents a 19.08% increase from the last price of $203.23.

$100 $140 $180 $220 $260 $300 High: $254 Avg: $242 Low: $230 Last Closed Price: $203.23

ASND Stock Rating

Ascendis Pharma stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (91.67%), 2 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 24 0 2 22 Strong Sell Sell Hold Buy Strong Buy

ASND Price Target Upside V Benchmarks

TypeNameUpside
StockAscendis Pharma19.08%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts123
Avg Price Target$254.00$242.00$221.33
Last Closing Price$203.23$203.23$203.23
Upside/Downside24.98%19.08%8.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25312---15
Sep, 25313---16
Aug, 25313---16
Jul, 25412---16
Jun, 25412---16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2025Li WatsekCantor Fitzgerald$254.00$209.5521.21%24.98%
Aug 08, 2025Luca IssiRBC Capital$230.00$191.4920.11%13.17%
Feb 18, 2025Morgan Stanley$180.00$144.0824.93%-11.43%
Sep 23, 2024Tazeen AhmadBank of America Securities$191.00$151.2626.27%-6.02%
Sep 17, 2024Gavin Clark-GartnerEvercore ISI$205.00$144.9741.41%0.87%
Sep 17, 2024Leland GershellOppenheimer$190.00$143.9032.04%-6.51%
Sep 17, 2024David LebowitzCitigroup$207.00$139.5748.31%1.86%
Sep 17, 2024Derek ArchilaWells Fargo$289.00$139.57107.06%42.20%
Sep 16, 2024Tazeen AhmadBank of America Securities$175.00$142.2623.01%-13.89%
Sep 16, 2024Paul ChoiGoldman Sachs$200.00$142.2640.59%-1.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2025Cantor FitzgeraldOverweightOverweighthold
Aug 08, 2025Cowen & Co.BuyBuyhold
Aug 08, 2025RBC CapitalOutperformOutperformhold
Aug 08, 2025UBSBuyBuyhold
Aug 08, 2025CitigroupBuyBuyhold
Aug 08, 2025Wells FargoOverweightOverweighthold
Jun 13, 2025OppenheimerOutperformOutperformhold
May 05, 2025Morgan StanleyEqual-WeightOverweightupgrade
May 02, 2025WedbushOutperformOutperformhold
Apr 15, 2025RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.28$-7.00$-10.40$-8.55-----
Avg Forecast$-7.61$-7.41$-9.55$-8.86$-6.98$-3.90$1.06$10.04$13.91
High Forecast$-6.20$-6.04$-7.77$-7.55$-5.72$-1.46$5.22$26.67$21.09
Low Forecast$-10.77$-10.50$-14.59$-10.95$-7.73$-6.36$-0.88$3.69$10.79
Surprise %8.80%-5.53%8.90%-3.50%-----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.95M$7.78M$51.17M$266.72M-----
Avg Forecast$8.95M$6.60M$45.90M$224.61M$300.07M$530.08M$1.00B$1.73B$2.32B
High Forecast$11.81M$8.71M$64.54M$279.10M$365.49M$749.98M$1.01B$2.41B$3.24B
Low Forecast$7.68M$5.66M$39.31M$194.11M$258.44M$448.72M$996.14M$1.43B$1.92B
Surprise %-22.30%17.89%11.49%18.75%-----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-418.95M$-383.58M$-583.19M$-481.45M-----
Avg Forecast$-428.16M$-417.32M$-537.67M$-437.49M$-381.83M$-196.74M$137.26M$538.04M$782.81M
High Forecast$-348.94M$-340.10M$-437.37M$-425.03M$-322.10M$-82.43M$293.94M$1.50B$1.19B
Low Forecast$-606.18M$-590.82M$-821.49M$-616.22M$-435.36M$-357.87M$-49.59M$207.64M$607.46M
Surprise %-2.15%-8.08%8.47%10.05%-----

ASND Forecast FAQ

Is Ascendis Pharma stock a buy?

Ascendis Pharma stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ascendis Pharma is a favorable investment for most analysts.

What is Ascendis Pharma's price target?

Ascendis Pharma's price target, set by 24 Wall Street analysts, averages $242 over the next 12 months. The price target range spans from $230 at the low end to $254 at the high end, suggesting a potential 19.08% change from the previous closing price of $203.23.

How does Ascendis Pharma stock forecast compare to its benchmarks?

Ascendis Pharma's stock forecast shows a 19.08% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ascendis Pharma over the past three months?

  • October 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ascendis Pharma’s EPS forecast?

Ascendis Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-6.98, marking a -18.36% decrease from the reported $-8.55 in 2023. Estimates for the following years are $-3.9 in 2025, $1.06 in 2026, $10.04 in 2027, and $13.91 in 2028.

What is Ascendis Pharma’s revenue forecast?

Ascendis Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $300.07M, reflecting a 12.50% increase from the reported $266.72M in 2023. The forecast for 2025 is $530.08M, followed by $1B for 2026, $1.73B for 2027, and $2.32B for 2028.

What is Ascendis Pharma’s net income forecast?

Ascendis Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-382M, representing a -20.69% decrease from the reported $-481M in 2023. Projections indicate $-197M in 2025, $137.26M in 2026, $538.04M in 2027, and $782.81M in 2028.